Status: Recruiting
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
Participants needed: 140
Trial details
Phase: Phase 1Age: 10-17Biological sex: AllType: InterventionalSponsor: BioXcel Therapeutics IncUpdated: Apr 13, 2026Locations: 5
Eligibility criteria
Male and female subjects between the ages of 10-17 years, inclusive, with bipola... [+3]
Patients with agitation caused by acute intoxication, including alcohol or drugs... [+5]